Listen to this Article Now
Former President John Dramani Mahama has praised research establishments in Ghana for the key job they played preceding the endorsement of the primary intestinal sickness immunization by the World Health Organization (WHO).
Mahama in a Facebook post featured the vigorous endeavors of Ghanaians scientists and foundations in Ghana that made the accomplishment conceivable.
“The Kintampo Health Research Center, Agogo Presbyterian Hospital, Navrongo Health Research Center, School of Public Health, University of Ghana, University of Health and Allied Sciences, the Noguchi Memorial Institute for Medical Research, and Kwame Nkrumah University of Science and Technology drove different clinical preliminaries of the Malaria Vaccine in Ghana,” Mahama posted on Facebook.
As indicated by Mahama, “This accomplishment is another justification for why we should put and fundamentally in state of the art science, innovative work in Ghana”.
Intestinal sickness stays one of the world’s driving executioners, killing one youngster at regular intervals. The vast majority of these passings are in Africa.
In Ghana, WHO information proposes that around 20% of all youngsters have jungle fever parasites in their blood.
Ghana was one of three African nations in which the intestinal sickness antibody, known as RTS,S, was made accessible for preliminaries on kids as long as 2 years old.
More than 800,000 youngsters were caught in the pilot stage in the three African nations beginning around 2019.
In Ghana, the antibody experimental run program was led in the Brong Ahafo, Central and Volta locales and a few areas in the Upper East district.
WHO accordingly supported the RTS,S/AS01 (RTS,S) intestinal sickness immunization among youngsters in sub-Saharan Africa and in different districts with moderate to high P. falciparum jungle fever transmission.
Mahama whose administration communicated interest in leading the preliminaries in Ghana is thrilled with the most recent turn of events.
He demanded that the “Specialized Working Group [that drove the clinical preliminaries in Ghana] merits National Awards.”
He had before praised the World Health Organization for supporting the main jungle fever immunization following quite a while of preliminaries.
Mr. Mahama ascribed the advancement settled on to his organization’s choice to permit the preliminary to be done in Ghana.
“It is inspiring to learn of the World Health Organization’s (WHO) endorsement of a jungle fever antibody following quite a while of preliminary. It is reviving and promising to discover that our appearance of interest in 2016 to the WHO and dynamic cooperation in the Malaria immunization experimental run program has prompted the endorsement of the antibody to be sent in Sub-Saharan Africa and other jungle fever endemic areas.”
“I’m happy at the possibility of immunizing a large number of African kids who will be saved from avoidable passings because of this logical and Public Health forward leap”.